XT1061
/ Xi’an XinTong Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 28, 2024
Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=128 | Recruiting | Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd.
New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation
1 to 1
Of
1
Go to page
1